Preeclampsia Gains New Attention from WHO and Biopharma After Years of Neglect

Key points

• Preeclampsia is a pregnancy-related hypertension disorder that impacts millions of mothers and newborns each year.
• The condition has historically been long ignored by drugmakers.
• The World Health Organization (WHO) and biopharmaceutical companies are now focusing on preeclampsia.
• This represents a shift in attention from top-level public health organizations toward this previously neglected condition.

Background

Preeclampsia has been a long-standing public health concern that was previously overlooked by the pharmaceutical industry. The recent attention from the WHO and biopharma companies marks a significant shift in how this condition is being addressed in global health and drug development.

Why it matters

The increased focus on preeclampsia by major health organizations and biopharmaceutical companies could lead to improved treatments and interventions for a condition that affects millions of mothers and newborns annually, potentially reducing associated health risks and improving outcomes for affected populations.

What to watch

The article does not provide specific next steps, but the increased attention from the WHO and biopharma companies suggests potential future developments in research, treatment options, and public health initiatives related to preeclampsia.